ZE74-0282 is a novel JAK2 JH2 domain inhibitor with promising preclinical activity in JAK2V617F mutant diseases
ZE74-0282 is a novel JAK2 JH2 domain inhibitor with promising preclinical activity in JAK2V617F mutant diseases
Discovery of a novel, selective brain penetrant CDK2 inhibitor for targeted cancer therapy
Discovery of a novel, selective brain penetrant CDK2 inhibitor for targeted cancer therapy
A Novel, wild-type sparing pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC
A Novel, wild-type sparing pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC
A novel Selective BCL2 inhibitor with limited immune suppression and improved safety compared to venetoclax
A novel Selective BCL2 inhibitor with limited immune suppression and improved safety compared to venetoclax
Therapeutic Targeting of FLT3 gate keeper mutation with E2082-0047 in traditional and a novel Immunocompetent murine adoptive transfer model of AML
Therapeutic Targeting of FLT3 gate keeper mutation with E2082-0047 in traditional and a novel Immunocompetent murine adoptive transfer model of AML
ASH2022: A Novel Inhibitor of FLT3 and its Drug-resistant Mutants with Superior Activity to Gilteritinib in MOLM-13 Preclinical Acute Myeloid Leukemia Xenograft Model
ASH2022: A Novel Inhibitor of FLT3 and its Drug-resistant Mutants with Superior Activity to Gilteritinib in MOLM-13 Preclinical Acute Myeloid Leukemia Xenograft Model